GO:0000309 nicotinamide-nucleotide adenylyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000309 describes the enzymatic activity that converts beta-nicotinamide D-ribonucleotide (NMN) and ATP into NAD+, a central redox cofactor and signaling molecule.
• The reaction is catalyzed by NMNAT enzymes (NMNAT1, NMNAT2, NMNAT3 in humans), which are compartmentalized to the nucleus, cytosol/Golgi, and mitochondria, respectively.
• NAD+ produced by this activity is essential for oxidative phosphorylation, DNA repair, and signaling, and its subcellular pools are interconnected and buffered by mitochondrial NAD+.
• Dysregulation of NMNAT1 is linked to alcohol-associated fatty liver disease, while NMNAT2 is critical for axon survival and is implicated in congenital neuropathy and programmed axon degeneration.
• Pharmacological targeting of NAD+ biosynthesis, including NMNAT-dependent steps, is being explored in glioblastoma and other cancers.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of NMNAT isoform-specific functions in health and disease.
Description
Nicotinamide-nucleotide adenylyltransferase activity (GO:0000309) is a molecular function that catalyzes the final step of NAD+ biosynthesis: the transfer of an adenylyl group from ATP to beta-nicotinamide D-ribonucleotide (NMN), yielding NAD+ and diphosphate. This activity is essential for maintaining cellular NAD+ levels, which are required for redox reactions, ATP production, and signaling processes. In humans, three NMNAT isoforms (NMNAT1, NMNAT2, NMNAT3) carry out this reaction in distinct subcellular compartments, and their specific roles have been illuminated by recent studies using genetically engineered models. Researchers study GO:0000309 because NAD+ homeostasis is central to metabolism, neuroprotection, and cancer biology. For example, NMNAT1 in the liver defends against alcohol-associated fatty liver disease, while NMNAT2 is critical for axon survival and its loss triggers Wallerian-like degeneration. Moreover, NAD+ biosynthetic enzymes are being explored as therapeutic targets in glioblastoma and as modulators of translation and proteostasis in cancer. Understanding this activity at the molecular level informs the development of CRISPR-based disease models and targeted therapies.
nicotinamide-nucleotide adenylyltransferase activity At A Glance
| GO ID | GO:0000309 |
|---|---|
| GO term | nicotinamide-nucleotide adenylyltransferase activity |
| Ontology | molecular_function |
| Synonym | NMN adenylyltransferase activity; NAD+ pyrophosphorylase activity; ATP:NMN adenylyltransferase activity |
| Major function | Catalyzes the final step of NAD+ biosynthesis from NMN and ATP |
| Reaction | beta-nicotinamide D-ribonucleotide + ATP + H+ = diphosphate + NAD+ |
| Human genes | NMNAT1, NMNAT2, NMNAT3 |
| Subcellular localization | NMNAT1: nucleus; NMNAT2: cytosol/Golgi; NMNAT3: mitochondria |
| Related pathways | NAD+ salvage, redox metabolism, axon survival, DNA repair |
What Is GO:0000309?
GO:0000309 is defined as the catalysis of the reaction: beta-nicotinamide D-ribonucleotide + ATP + H+ = diphosphate + NAD+. In simpler terms, it is the enzyme activity that attaches an adenylyl group from ATP to NMN, forming NAD+. This activity is also known by synonyms such as NMN adenylyltransferase activity, NAD+ pyrophosphorylase activity, and ATP:NMN adenylyltransferase activity.
Why Is nicotinamide-nucleotide adenylyltransferase activity Important in Cell Biology?
GO:0000309 is essential because it produces NAD+, a cofactor required for hundreds of redox reactions and signaling pathways. Without this activity, cells cannot maintain NAD+ pools, leading to metabolic collapse, neurodegeneration, and increased susceptibility to disease. Recent research highlights its role in liver disease, neuropathy, and cancer, making it a prime target for therapeutic intervention and CRISPR-based modeling.
• Maintains cellular NAD+ levels for energy metabolism and oxidative phosphorylation.
• Supports DNA repair and cell survival under stress by providing NAD+ for PARPs and sirtuins.
• NMNAT2 is critical for axon survival; its loss triggers Wallerian-like degeneration.
• NMNAT1 protects against alcohol-associated fatty liver disease.
• NAD+ biosynthesis is a metabolic vulnerability in glioblastoma and other cancers.
• Subcellular NAD+ pools are interconnected, with mitochondrial NAD+ buffering cytosolic and nuclear pools.
• Enables precise CRISPR models to study isoform-specific functions.
• Provides a target for pharmacological modulation of NAD+ levels in disease.
What Happens During nicotinamide-nucleotide adenylyltransferase activity?
Substrate binding and catalysis
In simple terms: The enzyme grabs NMN and ATP, then joins them together to make NAD+.
The reaction proceeds by binding beta-nicotinamide D-ribonucleotide (NMN) and ATP in the active site. The enzyme catalyzes the transfer of the adenylyl group from ATP to NMN, releasing diphosphate and forming NAD+. This activity is conserved across NMNAT isoforms and is essential for NAD+ biosynthesis.
Isoform-specific compartmentalization
In simple terms: Different versions of the enzyme work in different parts of the cell.
In humans, NMNAT1 localizes to the nucleus, NMNAT2 to the cytosol and Golgi, and NMNAT3 to mitochondria. This compartmentalization allows distinct NAD+ pools to be maintained and regulated independently, although they are interconnected and buffered by mitochondrial NAD+.
NAD+ pool maintenance and signaling
In simple terms: The NAD+ made by this enzyme is used for many cellular tasks, from energy production to signaling.
NAD+ produced by GO:0000309 is consumed by enzymes such as PARPs, sirtuins, and CD38. This continuous synthesis and consumption cycle maintains NAD+ homeostasis, which is critical for redox balance, DNA repair, and stress responses.
Role in axon survival and neurodegeneration
In simple terms: In neurons, this enzyme activity is needed to keep axons alive.
NMNAT2 is transported along axons and its loss leads to rapid NAD+ depletion and axon degeneration. This mechanism is central to congenital SARM1-dependent neuropathy and programmed axon degeneration, as shown in mouse models and human genetics.
Key Genes Involved in GO:0000309 nicotinamide-nucleotide adenylyltransferase activity
The following genes encode enzymes or related proteins that carry out or regulate nicotinamide-nucleotide adenylyltransferase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NMNAT1 | Nuclear NMNAT; catalyzes NAD+ synthesis from NMN and ATP | Mutations cause retinal degeneration; protects against fatty liver disease |
| NMNAT2 | Cytosolic/Golgi NMNAT; critical for axon survival | Loss triggers Wallerian-like degeneration; linked to congenital neuropathy |
| NMNAT3 | Mitochondrial NMNAT; maintains mitochondrial NAD+ pools | Buffers subcellular NAD+ pools; studied in metabolic disorders |
| NAMPT | Rate-limiting enzyme in NAD+ salvage pathway | Provides NMN for NMNAT; target in cancer and inflammation |
| NMRK1 | Phosphorylates nicotinamide riboside to NMN | Alternative route to NMN for NMNAT |
| NMRK2 | Phosphorylates nicotinamide riboside to NMN | Muscle-specific isoform; contributes to NAD+ synthesis |
| SARM1 | NAD+ hydrolase; promotes axon degeneration | Antagonizes NMNAT2; target in neuropathy |
| PARP1 | Consumes NAD+ for DNA repair | Links NMNAT activity to DNA damage responses |
| CD38 | NAD+ glycohydrolase | Regulates extracellular NAD+ levels; impacts NMNAT function |
| SIRT1 | NAD+-dependent deacetylase | Consumes NAD+; feedback regulation of NMNAT |
| SIRT3 | Mitochondrial NAD+-dependent deacetylase | Mitochondrial NAD+ sensor; interacts with NMNAT3 |
| ACMSD | Aminocarboxymuconate semialdehyde decarboxylase | Influences de novo NAD+ synthesis; affects NMNAT substrate availability |
| QPRT | Quinolinate phosphoribosyltransferase | De novo NAD+ pathway; provides NMN |
| NADSYN1 | NAD synthetase | Alternative NAD+ synthesis from NaAD |
| IDO1 | Indoleamine 2,3-dioxygenase | Tryptophan catabolism for de novo NAD+ synthesis |
| TDO2 | Tryptophan 2,3-dioxygenase | Liver-specific de novo NAD+ synthesis |
| GAPDH | Glycolytic enzyme | Moonlighting role in NAD+ regulation; not directly NMNAT |
How Is nicotinamide-nucleotide adenylyltransferase activity Regulated?
NMNAT activity is regulated at multiple levels. Subcellular localization determines which NAD+ pool is affected, and isoform-specific expression patterns contribute to tissue-specific NAD+ homeostasis. NMNAT2 is rapidly degraded when not transported, linking its regulation to axonal survival. Additionally, NAD+ consumption by PARPs and sirtuins creates a feedback loop that influences NMNAT demand.
nicotinamide-nucleotide adenylyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NMNAT1 | Alcohol-associated fatty liver disease; retinal degeneration | Liver-specific knockout mice; hepatocyte cell lines |
| NMNAT2 | Congenital neuropathy; Wallerian-like degeneration | NMNAT2 knockout mice; neuronal cultures |
| NMNAT3 | Mitochondrial dysfunction; metabolic disorders | NMNAT3 knockout cells; mitochondrial NAD+ biosensors |
| SARM1 | Axon degeneration; neuropathy | SARM1 knockout mice; human iPSC-derived neurons |
| NAMPT | Cancer; inflammation | NAMPT inhibitors in glioblastoma models |
Neurodegeneration and axonopathies
NMNAT2 is essential for axon survival, and its deficiency leads to SARM1-dependent axon degeneration. This mechanism is implicated in congenital neuropathy and other neurodegenerative conditions. NMNAT1 mutations cause retinal degeneration, and NMNAT3 dysfunction may affect mitochondrial health.
Metabolic and liver diseases
Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease, highlighting the role of nuclear NAD+ synthesis in liver metabolism. Mitochondrial NAD+ buffering by NMNAT3 also influences systemic metabolic homeostasis.
Cancer
NAD+ biosynthesis supports cancer cell proliferation and survival. Gliocidin, a nicotinamide-mimetic prodrug, targets glioblastoma by exploiting NAD+ metabolism. Ribosome ADP-ribosylation, which consumes NAD+, inhibits translation and maintains proteostasis in cancers, linking NMNAT activity to translational control.
From nicotinamide-nucleotide adenylyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NMNAT1 loss affect liver lipid metabolism? | Liver-specific NMNAT1 knockout mouse |
| Is NMNAT2 required for axon survival in vivo? | NMNAT2 conditional knockout mouse |
| How does NMNAT3 contribute to mitochondrial NAD+ pools? | NMNAT3 knockout cells with targeted NAD+ biosensors |
| Can a point mutation in NMNAT1 alter catalytic activity? | CRISPR knock-in of patient-derived mutations |
| Does overexpression of NMNAT2 protect against axon degeneration? | AAV-mediated NMNAT2 overexpression in neurons |
| What is the role of NMNAT1 in cancer cell proliferation? | NMNAT1 knockout cancer cell lines |
How to Study the nicotinamide-nucleotide adenylyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | NMNAT catalytic activity | Recombinant enzyme kinetics |
| NAD+ biosensor imaging | Subcellular NAD+ levels | Live-cell compartmentalization studies |
| CRISPR knockout | Gene function loss | Identifying essential NAD+ synthesis genes |
| RNA-seq | Transcriptional changes | Pathway analysis after NMNAT perturbation |
| Ribo-seq | Translation efficiency | Proteostasis and ribosome ADP-ribosylation |
| Proteomics | Protein abundance and modifications | NAD+ interactome and PARylation |
| Axon degeneration assay | Axon survival | NMNAT2/SARM1 mechanism studies |
Enzymatic assays for NMNAT activity
Direct measurement of GO:0000309 activity can be performed using recombinant NMNAT isoforms and substrates NMN and ATP, followed by detection of NAD+ by HPLC or coupled enzymatic assays.
Genetically encoded NAD+ biosensors
Fluorescent biosensors such as Peredox or NAD+ sensors enable real-time monitoring of subcellular NAD+ levels in live cells, revealing the contribution of NMNAT isoforms to compartmentalized NAD+ pools.
CRISPR screening and knockout models
Genome-wide CRISPR knockout screens can identify genes that modulate NAD+ dependence, including NMNAT isoforms. Targeted knockouts in cell lines and mice provide causal insights into disease mechanisms.
Transcriptomics and proteomics
RNA-seq and proteomics can reveal changes in NAD+ metabolism pathways upon NMNAT manipulation. Ribosome profiling (Ribo-seq) can assess translational effects linked to NAD+ depletion.
How CRISPR Can Be Used to Study GO:0000309 nicotinamide-nucleotide adenylyltransferase activity
Knockout
CRISPR knockout of NMNAT1, NMNAT2, or NMNAT3 in cell lines and mice enables loss-of-function studies to determine isoform-specific roles in NAD+ homeostasis and disease. For example, liver-specific NMNAT1 knockout exacerbates fatty liver disease, and NMNAT2 knockout triggers axon degeneration.
Point Mutation
Introducing patient-derived point mutations into NMNAT genes via CRISPR base editing or HDR can model catalytic deficiencies or altered localization. This approach helps dissect the impact of specific residues on enzymatic activity and disease phenotypes.
Knock-in
Knock-in of tagged NMNAT alleles (e.g., GFP or HA) allows visualization and immunoprecipitation of endogenous proteins. This is useful for tracking subcellular localization and interaction partners in vivo.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of NMNAT isoforms can test sufficiency in rescuing NAD+ depletion or protecting against degeneration. For instance, NMNAT2 overexpression may protect axons from SARM1-dependent degeneration.
How EDITGENE Supports nicotinamide-nucleotide adenylyltransferase activity Research
Researchers studying nicotinamide-nucleotide adenylyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in NAD+ metabolism, neurodegeneration, or cancer. EDITGENE provides tailored CRISPR solutions to generate precisely engineered cell and animal models, accelerating functional validation and therapeutic development.
Contact EDITGENE today to design your custom CRISPR model for nicotinamide-nucleotide adenylyltransferase activity research.
Frequently Asked Questions About nicotinamide-nucleotide adenylyltransferase activity
What is nicotinamide-nucleotide adenylyltransferase activity?
It is the enzyme activity (GO:0000309) that catalyzes the conversion of NMN and ATP to NAD+ and diphosphate, the final step in NAD+ biosynthesis.
What genes encode nicotinamide-nucleotide adenylyltransferase activity?
In humans, the NMNAT1, NMNAT2, and NMNAT3 genes encode enzymes with this activity, localized to the nucleus, cytosol/Golgi, and mitochondria, respectively.
What diseases are linked to NMNAT genes?
NMNAT1 is linked to fatty liver disease and retinal degeneration; NMNAT2 is linked to congenital neuropathy and axon degeneration; NMNAT3 may affect mitochondrial and metabolic disorders.
How is NMNAT activity measured?
It can be measured using recombinant enzymes with NMN and ATP, followed by NAD+ detection via HPLC or coupled assays, or by using genetically encoded NAD+ biosensors in live cells.
What is the role of NMNAT2 in neurons?
NMNAT2 is critical for axon survival; its loss leads to rapid NAD+ depletion and SARM1-dependent axon degeneration.
Can CRISPR be used to study NMNAT function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of NMNAT isoform-specific roles in cells and animals.
Is NMNAT a target for cancer therapy?
NAD+ biosynthesis, including NMNAT-dependent steps, is a metabolic vulnerability in cancers such as glioblastoma, and prodrugs like gliocidin target this pathway.
What is the reaction catalyzed by GO:0000309?
The reaction is: beta-nicotinamide D-ribonucleotide + ATP + H+ = diphosphate + NAD+.
How do subcellular NAD+ pools relate to NMNAT isoforms?
Distinct NMNAT isoforms maintain separate NAD+ pools that are interconnected and buffered by mitochondrial NAD+.
What model systems are used to study NMNAT1 in liver disease?
Liver-specific NMNAT1 knockout mice and hepatocyte cell lines are used to study alcohol-associated fatty liver disease.
Conclusion
Nicotinamide-nucleotide adenylyltransferase activity (GO:0000309) is a fundamental enzymatic function that produces NAD+, a molecule central to metabolism, signaling, and survival. The three human NMNAT isoforms serve distinct subcellular roles, and their dysfunction is implicated in liver disease, neurodegeneration, and cancer. CRISPR-based models are powerful tools to dissect these isoform-specific functions and to evaluate therapeutic strategies targeting NAD+ metabolism.
References
- 1. Chen YJ et al.. 2024. Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma.. Nature 636(8042):466-473 PMID: 39567689
- 2. Ding Q et al.. 2025. Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease.. Sci Adv 11(26):eadt6195 PMID: 40577472
- 3. Ng CSC et al.. 2024. Targeted protein relocalization via protein transport coupling.. Nature 633(8031):941-951 PMID: 39294374
- 4. Cambronne XA et al.. 2016. Biosensor reveals multiple sources for mitochondrial NAD⁺.. Science 352(6292):1474-7 PMID: 27313049
- 5. Challa S et al.. 2021. Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers.. Cell 184(17):4531-4546.e26 PMID: 34314702
- 6. Dingwall CB et al.. 2022. Macrophage depletion blocks congenital SARM1-dependent neuropathy.. J Clin Invest 132(23) PMID: 36287209
- 7. Hopkins EL et al.. 2026. Programmed axon degeneration gene variants in human disease.. Exp Neurol 404:115891 PMID: 42341897
- 8. Høyland LE et al.. 2024. Subcellular NAD(+) pools are interconnected and buffered by mitochondrial NAD().. Nat Metab 6(12):2319-2337 PMID: 39702414
